Literature DB >> 23175355

Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.

Wendy G Tan1, Hyun-Tak Jin, Erin E West, Pablo Penaloza-MacMaster, Andreas Wieland, Michael J Zilliox, M Juliana McElrath, Dan H Barouch, Rafi Ahmed.   

Abstract

Adenovirus (Ad) vectors are widely used as experimental vaccines against several infectious diseases, but the magnitude, phenotype, and functionality of CD8(+) T cell responses induced by different adenovirus serotypes have not been compared. To address this question, we have analyzed simian immunodeficiency virus Gag-specific CD8(+) T cell responses in mice following vaccination with Ad5, Ad26, and Ad35. Our results show that although Ad5 is more immunogenic than Ad26 and Ad35, the phenotype, function, and recall potential of memory CD8(+) T cells elicited by these vectors are substantially different. Ad26 and Ad35 vectors generated CD8(+) T cells that display the phenotype and function of long-lived memory T cells, whereas Ad5 vector-elicited CD8(+) T cells are of a more terminally differentiated phenotype. In addition, hepatic memory CD8(+) T cells elicited by Ad26 and Ad35 mounted more robust recall proliferation following secondary challenge than those induced by Ad5. Furthermore, the boosting potential was higher following priming with alternative-serotype Ad vectors than with Ad5 vectors in heterologous prime-boost regimens. Anamnestic CD8(+) T cell responses were further enhanced when the duration between priming and boosting was extended from 30 to 60 days. Our results demonstrate that heterologous prime-boost vaccine regimens with alternative-serotype Ad vectors elicited more functional memory CD8(+) T cells than any of the regimens containing Ad5. In summary, these results suggest that alternative-serotype Ad vectors will prove useful as candidates for vaccine development against human immunodeficiency virus type 1 and other pathogens and also emphasize the importance of a longer rest period between prime and boost for generating optimal CD8(+) T cell immunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23175355      PMCID: PMC3554140          DOI: 10.1128/JVI.02055-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes.

Authors:  David R Kaufman; Maytal Bivas-Benita; Nathaniel L Simmons; Darby Miller; Dan H Barouch
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

Review 2.  Migration, maintenance and recall of memory T cells in peripheral tissues.

Authors:  David L Woodland; Jacob E Kohlmeier
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

3.  Ly6C supports preferential homing of central memory CD8+ T cells into lymph nodes.

Authors:  Arno Hänninen; Mikael Maksimow; Catharina Alam; David J Morgan; Sirpa Jalkanen
Journal:  Eur J Immunol       Date:  2011-02-10       Impact factor: 5.532

Review 4.  Cytokines and the inception of CD8 T cell responses.

Authors:  Maureen A Cox; Laurie E Harrington; Allan J Zajac
Journal:  Trends Immunol       Date:  2011-03-02       Impact factor: 16.687

5.  Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.

Authors:  Norman L Letvin; Srinivas S Rao; David C Montefiori; Michael S Seaman; Yue Sun; So-Yon Lim; Wendy W Yeh; Mohammed Asmal; Rebecca S Gelman; Ling Shen; James B Whitney; Cathal Seoighe; Miguel Lacerda; Sheila Keating; Philip J Norris; Michael G Hudgens; Peter B Gilbert; Adam P Buzby; Linh V Mach; Jinrong Zhang; Harikrishnan Balachandran; George M Shaw; Stephen D Schmidt; John-Paul Todd; Alan Dodson; John R Mascola; Gary J Nabel
Journal:  Sci Transl Med       Date:  2011-05-04       Impact factor: 17.956

6.  Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Authors:  Thomas W Geisbert; Michael Bailey; Lisa Hensley; Clement Asiedu; Joan Geisbert; Daphne Stanley; Anna Honko; Joshua Johnson; Sabue Mulangu; Maria Grazia Pau; Jerome Custers; Jort Vellinga; Jenny Hendriks; Peter Jahrling; Mario Roederer; Jaap Goudsmit; Richard Koup; Nancy J Sullivan
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

7.  Comparison of adenoviruses from species B, C, E, and F after intravenous delivery.

Authors:  Daniel Stone; Ying Liu; Zong-Yi Li; Sebastian Tuve; Robert Strauss; André Lieber
Journal:  Mol Ther       Date:  2007-09-25       Impact factor: 11.454

8.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

Review 9.  From vaccines to memory and back.

Authors:  Federica Sallusto; Antonio Lanzavecchia; Koichi Araki; Rafi Ahmed
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

10.  Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.

Authors:  Jinyan Liu; Kara L O'Brien; Diana M Lynch; Nathaniel L Simmons; Annalena La Porte; Ambryice M Riggs; Peter Abbink; Rory T Coffey; Lauren E Grandpre; Michael S Seaman; Gary Landucci; Donald N Forthal; David C Montefiori; Angela Carville; Keith G Mansfield; Menzo J Havenga; Maria G Pau; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2008-11-09       Impact factor: 49.962

View more
  48 in total

Review 1.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

2.  Adenovirus vector-induced CD8⁺ T effector memory cell differentiation and recirculation, but not proliferation, are important for protective immunity against experimental Trypanosoma cruzi Infection.

Authors:  José Ronnie Vasconcelos; Mariana R Dominguez; Ramon L Neves; Jonatan Ersching; Adriano Araújo; Luara I Santos; Fernando S Virgilio; Alexandre V Machado; Oscar Bruna-Romero; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Hum Gene Ther       Date:  2014-03-31       Impact factor: 5.695

Review 3.  Success and failure of the cellular immune response against HIV-1.

Authors:  Stephen A Migueles; Mark Connors
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

4.  Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations.

Authors:  Maria Lisa Knudsen; Karl Ljungberg; Maria Kakoulidou; Linda Kostic; David Hallengärd; Juan García-Arriaza; Andres Merits; Mariano Esteban; Peter Liljeström
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

5.  Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.

Authors:  Pablo Penaloza-MacMaster; Jeffrey E Teigler; Rebecca C Obeng; Zi H Kang; Nicholas M Provine; Lily Parenteau; Stephen Blackmore; Joshua Ra; Erica N Borducchi; Dan H Barouch
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

6.  HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.

Authors:  Pierre-Alexandre Bart; Yunda Huang; Shelly T Karuna; Samuel Chappuis; Julien Gaillard; Nidhi Kochar; Xiaoying Shen; Mary A Allen; Song Ding; John Hural; Hua-Xin Liao; Barton F Haynes; Barney S Graham; Peter B Gilbert; M Juliana McElrath; David C Montefiori; Georgia D Tomaras; Giuseppe Pantaleo; Nicole Frahm
Journal:  J Clin Invest       Date:  2014-10-01       Impact factor: 14.808

7.  Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.

Authors:  Eric A Weaver
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

8.  Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

Authors:  Nicholas M Provine; Rafael A Larocca; Pablo Penaloza-MacMaster; Erica N Borducchi; Anna McNally; Lily R Parenteau; David R Kaufman; Dan H Barouch
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

9.  A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.

Authors:  Monica Cabrera-Mora; Jairo Andres Fonseca; Balwan Singh; Chunxia Zhao; Natalia Makarova; Igor Dmitriev; David T Curiel; Jerry Blackwell; Alberto Moreno
Journal:  J Immunol       Date:  2016-08-29       Impact factor: 5.422

10.  Qualitative and quantitative analysis of adenovirus type 5 vector-induced memory CD8 T cells: not as bad as their reputation.

Authors:  Maria Abildgaard Steffensen; Peter Johannes Holst; Sanne Skovvang Steengaard; Benjamin Anderschou Holbech Jensen; Christina Bartholdy; Anette Stryhn; Jan Pravsgaard Christensen; Allan Randrup Thomsen
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.